Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1635jle

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 17:27:24 ON 06 JUN 2006

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:27:41 ON 06 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     5 JUN 2006  HIGHEST RN 886840-90-0
DICTIONARY FILE UPDATES:    5 JUN 2006  HIGHEST RN 886840-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s human growth hormone receptor
       4979340 HUMAN
          6505 HUMANS
       4985844 HUMAN
                 (HUMAN OR HUMANS)
         22268 GROWTH
         10688 HORMONE
            87 HORMONES
         10688 HORMONE
                 (HORMONE OR HORMONES)
        101271 RECEPTOR
           872 RECEPTORS
        101918 RECEPTOR
                 (RECEPTOR OR RECEPTORS)
L1          23 HUMAN GROWTH HORMONE RECEPTOR
                 (HUMAN(W)GROWTH(W)HORMONE(W)RECEPTOR)

=> file caplus, uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
```

FULL ESTIMATED COST 19.48 19.69

FILE 'CAPLUS' ENTERED AT 17:28:05 ON 06 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'USPATFULL' ENTERED AT 17:28:05 ON 06 JUN 2006

=> s l1 and (antisense or siRNA or RNAi or dsRNA or ribozyme or triplex or oligonucleotide)
L2 2 FILE CAPLUS
L3 3 FILE USPATFULL

TOTAL FOR ALL FILES
L4 5 L1 AND (ANTISENSE OR SIRNA OR RNAI OR DSRNA OR RIBOZYME OR TRIPLEX OR OLIGONUCLEOTIDE)

=> d ibib abs 1-5 fhistr
'FHISTR' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib abs fhitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1335158 CAPLUS
DOCUMENT NUMBER: 144:81464
TITLE: **Oligonucleotides** specific to growth hormone receptor for modulation of growth hormone receptor and/or insulin-like growth factor expression, and therapeutic and dignostic uses
INVENTOR(S): Tachas, George; Dobie, Kenneth W.; Jain, Ravi; Belyea, Christopher I.; Heffernan, Mark A.
PATENT ASSIGNEE(S): Australia
SOURCE: U.S. Pat. Appl. Publ., 132 pp., Cont.-in-part of U.S. Ser. No. 789,526.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005282761	A1	20051222	US 2004-927466		20040825
US 2004253723	A1	20041216	US 2004-789526		20040226
PRIORITY APPLN. INFO.:			US 2003-451455P	P	20030228
			US 2003-490230P	P	20030725
			US 2004-789526	A2	20040226

AB The invention provides **antisense oligonucleotide** compns., which hybridize with nucleic acid encoding growth hormone receptor. The **oligonucleotides** included chimeric **oligonucleotides** having phosphorothioate internucleoside linkages, sugar moiety, or modified nucleobase, such as 5-methylcytosine. Methods of using these compns. and compds. for modulating the expression of growth hormone receptor (GHR) and/or insulin like growth factor-I (IGF-I) and for diagnosis and treatment of disease associated with expression of GHR and/or IGF-I are also provided. Diagnostic methods and kits including GHR-specific primers and probes are also provided.
IT **872063-53-1**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; **oligonucleotides** specific to growth hormone receptor (GHR) for modulation of GHR and/or insulin-like growth factor expression, and therapeutic and dignostic uses)

RN 872063-53-1 CAPLUS

CN DNA (human growth hormone receptor cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:756831 CAPLUS

DOCUMENT NUMBER: 141:271997

TITLE: Methods for the synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) modulators and therapeutic uses thereof

INVENTOR(S): Tachas, George; Dobie, Kenneth

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078922	A2	20040916	WO 2004-US5896	20040227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004253723	A1	20041216	US 2004-789526	20040226
AU 2004217508	A1	20040916	AU 2004-217508	20040227
CA 2517101	AA	20040916	CA 2004-2517101	20040227
PRIORITY APPLN. INFO.:			US 2003-451455P P	20030228
			US 2003-490230P P	20030725
			US 2004-789526 A	20040226
			WO 2004-US5896 W	20040227

AB Compds., compns. and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compns. comprise **oligonucleotides**, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compds. for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

IT **757999-69-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; methods for synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) oligonucleotidic modulators and therapeutic uses thereof)

RN 757999-69-2 CAPLUS

CN DNA (human growth hormone receptor plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:324849 USPATFULL

TITLE: Modulation of growth hormone receptor expression and

insulin-like growth factor expression

INVENTOR(S): Tachas, George, Melbourne, AUSTRALIA
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Jain, Ravi, Carlsbad, CA, UNITED STATES
Belyea, Christopher I., Melbourne, AUSTRALIA
Heffernan, Mark A., Melbourne, AUSTRALIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005282761	A1	20051222
APPLICATION INFO.:	US 2004-927466	A1	20040825 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-789526, filed on 26 Feb 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-451455P	20030228 (60)
	US 2003-490230P	20030725 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE, MARTENS, OLSON & BEAR, LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 6871
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise **oligonucleotides**, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **872063-53-1**
(nucleotide sequence; oligonucleotides specific to growth hormone receptor (GHR) for modulation of GHR and/or insulin-like growth factor expression, and therapeutic and dignostic uses)
RN 872063-53-1 USPATFULL
CN DNA (human growth hormone receptor cDNA plus flanks) (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L4 ANSWER 4 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2004:321070 USPATFULL
TITLE: Modulation of growth hormone receptor expression and insulin-like growth factor expression
INVENTOR(S): Tachas, George, Melbourne, AUSTRALIA
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Jain, Ravi, Carlsbad, CA, UNITED STATES
Belyea, Christopher, Melbourne, AUSTRALIA
Heffernan, Mark A., Melbourne, AUSTRALIA
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, 92008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004253723	A1	20041216
APPLICATION INFO.:	US 2004-789526	A1	20040226 (10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2003-451455P 20030228 (60)
US 2003-490230P 20030725 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FENWICK & WEST LLP, 801 CALIFORNIA STREET, MOUNTAIN VIEW, CA, 94014
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise **oligonucleotides**, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **757999-69-2**
(nucleotide sequence; methods for synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) oligonucleotidic modulators and therapeutic uses thereof)
RN 757999-69-2 USPATFULL
CN DNA (human growth hormone receptor plus flanks) (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L4 ANSWER 5 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2004:94203 USPATFULL
TITLE: Binding agent
INVENTOR(S): Ross, Richard, Sheffield, UNITED KINGDOM
Artymiuk, Peter, Sheffield, UNITED KINGDOM
Sayers, Jon, Sheffield, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004071655	A1	20040415	
APPLICATION INFO.:	US 2003-311473	A1	20030718	(10)
	WO 2001-GB2645		20010618	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-14765	20000616
	GB 2001-5969	20010310
	GB 2001-6487	20010316

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 1371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **382709-20-8**
(nucleotide sequence; chimeric binding agent comprising cytokine, linker and cytokine receptor and uses in modulating receptor activity and therapy)

RN 382709-20-8 USPATFULL
CN DNA (synthetic human somatotropin fusion protein with synthetic human growth hormone receptor-specifying) (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

=> d his

(FILE 'HOME' ENTERED AT 17:27:24 ON 06 JUN 2006)

FILE 'REGISTRY' ENTERED AT 17:27:41 ON 06 JUN 2006
L1 23 S HUMAN GROWTH HORMONE RECEPTOR

FILE 'CAPLUS, USPATFULL' ENTERED AT 17:28:05 ON 06 JUN 2006
L2 2 FILE CAPLUS
L3 3 FILE USPATFULL
TOTAL FOR ALL FILES
L4 5 S L1 AND (ANTISENSE OR SIRNA OR RNAI OR DSRNA OR RIBOZYME OR TR

=> s l1
L5 12 FILE CAPLUS
L6 4 FILE USPATFULL

TOTAL FOR ALL FILES
L7 16 L1

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8 15 DUP REM L7 (1 DUPLICATE REMOVED)

=> d ibib abs 1-15

L8 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:1335158 CAPLUS
DOCUMENT NUMBER: 144:81464
TITLE: Oligonucleotides specific to growth hormone receptor for modulation of growth hormone receptor and/or insulin-like growth factor expression, and therapeutic and dignostic uses
INVENTOR(S): Tachas, George; Dobie, Kenneth W.; Jain, Ravi; Belyea, Christopher I.; Heffernan, Mark A.
PATENT ASSIGNEE(S): Australia
SOURCE: U.S. Pat. Appl. Publ., 132 pp., Cont.-in-part of U.S. Ser. No. 789,526.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005282761	A1	20051222	US 2004-927466		20040825
US 2004253723	A1	20041216	US 2004-789526		20040226
PRIORITY APPLN. INFO.:			US 2003-451455P	P	20030228
			US 2003-490230P	P	20030725
			US 2004-789526	A2	20040226

AB The invention provides antisense oligonucleotide compns., which hybridize with nucleic acid encoding growth hormone receptor. The oligonucleotides included chimeric oligonucleotides having phosphorothioate internucleoside linkages, sugar moiety, or modified nucleobase, such as 5-methylcytosine. Methods of using these compns. and compds. for modulating the expression of growth hormone receptor (GHR) and/or insulin like growth factor-I (IGF-I) and for diagnosis and treatment of disease associated with expression

of GHR and/or IGF-I are also provided. Diagnostic methods and kits including GHR-specific primers and probes are also provided.

L8 ANSWER 2 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2005:69436 USPATFULL
TITLE: Glycosylphosphatidylinositol containing polypeptides
INVENTOR(S): Ross, Richard, Sheffield, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005059577	A1	20050317	
APPLICATION INFO.:	US 2004-492403	A1	20040413	(10)
	WO 2002-GB4665		20021011	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-24620	20011013
	GB 2002-904	20020116
	GB 2002-18889	20020814

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: CLM-01-27
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 1521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to polypeptides which comprise a receptor binding domain of a cytokine and a domain which includes a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. The invention also relates to methods to manufacture the polypeptides, nucleic acids molecules encoding the polypeptides and therapeutic compositions comprising the polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:878488 CAPLUS
DOCUMENT NUMBER: 141:344597
TITLE: Chimeric proteins containing cytokine receptor binding domain and glycosylphosphatidylinositol anchor and their therapeutic uses
INVENTOR(S): Ross, Richard; Sayers, Jon; Artymiuk, Peter
PATENT ASSIGNEE(S): Asterion Limited, UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004090135	A2	20041021	WO 2004-GB1572	20040407
WO 2004090135	A3	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1616010	A2	20060118	EP 2004-726219	20040407

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.:	GB 2003-8088	A 20030409
	GB 2003-24235	A 20031016
	WO 2004-GB1572	W 20040407

AB The present invention relates to polypeptides which comprise a ligand-binding domain of a cytokine receptor fused with a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. GPI-anchors are post-translational modifications to proteins that add glycosylphosphatidylinositol which enable these proteins to anchor to the extracellular side of cell membranes. 1B1-GP1 was constructed, in which GH was linked through its C-terminus to the extracellular domain of the GH receptor and then linked to the GPI signal sequence. 1C1-GPI was also constructed, in which a tandem of GH was linked through the second GH C-terminus to the GPI signal sequence. The invention provides vectors and CHO-K1 cells for expressing GHBP-GPI.

L8 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2004:756831 CAPLUS
DOCUMENT NUMBER:	141:271997
TITLE:	Methods for the synthesis and screening of insulin-like growth factor-I (IGF-I) and growth hormone receptor (GHR) modulators and therapeutic uses thereof
INVENTOR(S):	Tachas, George; Dobie, Kenneth
PATENT ASSIGNEE(S):	Isis Pharmaceuticals, Inc., USA
SOURCE:	PCT Int. Appl., 293 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078922	A2	20040916	WO 2004-US5896	20040227

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004253723	A1	20041216	US 2004-789526	20040226
AU 2004217508	A1	20040916	AU 2004-217508	20040227
CA 2517101	AA	20040916	CA 2004-2517101	20040227
PRIORITY APPLN. INFO.:			US 2003-451455P	P 20030228
			US 2003-490230P	P 20030725
			US 2004-789526	A 20040226
			WO 2004-US5896	W 20040227

AB Compds., compns. and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compns. comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compds. for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

L8 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2004:321070 USPATFULL

TITLE: Modulation of growth hormone receptor expression and insulin-like growth factor expression
INVENTOR(S): Tachas, George, Melbourne, AUSTRALIA
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Jain, Ravi, Carlsbad, CA, UNITED STATES
Belyea, Christopher, Melbourne, AUSTRALIA
Heffernan, Mark A., Melbourne, AUSTRALIA
PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., Carlsbad, CA, 92008 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004253723	A1	20041216	
APPLICATION INFO.:	US 2004-789526	A1	20040226	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-451455P	20030228	(60)
	US 2003-490230P	20030725	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FENWICK & WEST LLP, 801 CALIFORNIA STREET, MOUNTAIN VIEW, CA, 94014
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 6798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:94203 USPATFULL
TITLE: Binding agent
INVENTOR(S): Ross, Richard, Sheffield, UNITED KINGDOM
Artymiuk, Peter, Sheffield, UNITED KINGDOM
Sayers, Jon, Sheffield, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004071655	A1	20040415	
APPLICATION INFO.:	US 2003-311473	A1	20030718	(10)
	WO 2001-GB2645		20010618	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-14765	20000616
	GB 2001-5969	20010310
	GB 2001-6487	20010316

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 1371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:180984 CAPLUS
DOCUMENT NUMBER: 140:194483
TITLE: Chimeric proteins containing cytokine receptor binding domain and glycosylphosphatidylinositol-containing signaling peptide and their therapeutic uses
INVENTOR(S): Ross, Richard
PATENT ASSIGNEE(S): Asterion Ltd., UK
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003034275	A2	20030424	WO 2002-GB4665	20021011
WO 2003034275	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2380735	A1	20030416	GB 2001-24620	20011013
CA 2494706	AA	20030424	CA 2002-2494706	20021011
JP 2005505307	T2	20050224	JP 2003-536934	20021011
US 2005059577	A1	20050317	US 2004-492403	20040413

PRIORITY APPLN. INFO.:		
GB 2001-24620	A	20011013
GB 2002-904	A	20020116
GB 2002-18889	A	20020814
WO 2002-GB4665	W	20021011

AB The present invention relates to polypeptides which comprise a cytokine-binding domain of a cytokine receptor fused with a signal sequence for the attachment of glycosylphosphatidylinositol (GPI) anchors. The cytokine receptor variants lack a cytoplasmic domain and therefore do not have the capability to signal. The provision of a GPI-anchor domain means the variant inserts into membranes and acts as an effective inhibitor of GH signaling by competing for circulating cytokine and binding cytokine at the cell surface in a heterodimeric complex that consists of the chimeric truncated GPI anchored receptor, cytokine, and the native receptor. In addition, truncated GPI-anchored receptor generates a large amount of soluble receptor which will bind its ligand. In a preferred embodiment, the chimeric protein acts as an antagonist following local or transgenic expression through gene therapy. Thus, the cDNA extracellular domain of human growth hormone receptor (bases 98-834 of GenBank X06562) is ligated into a vector (pAc6-LP-MCS-GPI) containing the Dictyostelium actin 6 gene promoter, a Dictyostelium signal peptide coding region, multiple, cloning site, and the signal for a GPI anchor, and the construct is transfected into Dicytostelium cells. To demonstrate that growth hormone receptor-GPI can act as a transgenic therapy, the extracellular domain of the growth hormone receptor is cloned upstream of a human GPI signal sequence into a mammalian expression vector.

L8 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:300688 CAPLUS
DOCUMENT NUMBER: 138:315840
TITLE: Preparation of GPI-anchored proteins with cytokine receptor ligand binding domain and signal sequence
INVENTOR(S): Ross, Richard
PATENT ASSIGNEE(S): Asterion Limited, UK
SOURCE: Brit. UK Pat. Appl., 41 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2380735	A1	20030416	GB 2001-24620	20011013
CA 2494706	AA	20030424	CA 2002-2494706	20021011
WO 2003034275	A2	20030424	WO 2002-GB4665	20021011
WO 2003034275	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1568330	A	20050119	CN 2002-820277	20021011
JP 2005505307	T2	20050224	JP 2003-536934	20021011
US 2005059577	A1	20050317	US 2004-492403	20040413

PRIORITY APPLN. INFO.:

GB 2001-24620	A	20011013
GB 2002-904	A	20020116
GB 2002-18889	A	20020814
WO 2002-GB4665	W	20021011

AB The present invention relates to polypeptides which comprise a receptor binding domain of a cytokine and a domain which includes a signal sequence for the attachment of glycosylphosphhatidylinositol (GPI) anchors. The invention also relates to methods to manufacture the polypeptides, nucleic acids, mols. encoding the polypeptides and therapeutic compns. by comprising the polypeptides.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:924005 CAPLUS
DOCUMENT NUMBER: 136:49347
TITLE: Chimeric binding agent comprising cytokine, linker and cytokine receptor and uses in modulating receptor activity and therapy
INVENTOR(S): Ross, Richard; Artymiuk, Peter; Sayers, Jon
PATENT ASSIGNEE(S): Asterion Limited, UK
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096565	A2	20011220	WO 2001-GB2645	20010618
WO 2001096565	A3	20020801		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2447632	AA	20011220	CA 2001-2447632		20010618
EP 1290170	A2	20030312	EP 2001-940731		20010618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004503243	T2	20040205	JP 2002-510682		20010618
US 2004071655	A1	20040415	US 2003-311473		20030718
PRIORITY APPLN. INFO.:			GB 2000-14765	A	20000616
			GB 2001-5969	A	20010310
			GB 2001-6487	A	20010316
			WO 2001-GB2645	W	20010618

AB The invention provides a binding agent comprising a first part capable of binding a ligand binding domain of a receptor linked to a second part comprising a receptor binding domain wherein said binding agent modulates the activity of the receptor. The inventors link growth hormone (GH), through its C-terminal and a linker to the N-terminus of the SD100 domain of growth hormone receptor (GHR). By varying the length of the linker inventors define a mol. that has the flexibility to allow binding of GH through site 1 to full length receptor at the cell surface. The invention also relates to methods, vectors and host cells for production of said chimeric binding agent.

L8 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:322773 CAPLUS
DOCUMENT NUMBER:	136:32454
TITLE:	Organization and evolution of the human growth hormone receptor gene 5'-flanking region
AUTHOR(S):	Goodyer, C. G.; Zogopoulos, G.; Schwartzbauer, G.; Zheng, H.; Hendy, G. N.; Menon, R. K.
CORPORATE SOURCE:	Departments of Pediatrics, Medicine, McGill University, Montreal, QC, H3Z 2Z3, Can.
SOURCE:	Endocrinology (2001), 142(5), 1923-1934 CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER:	Endocrine Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Previous studies have identified eight variant human GH receptor (hGHR) mRNA (mRNAs; V1-V8), that differ in their 5'-untranslated regions (5'UTRs) but splice into the same site just upstream of the translation start site in exon 2; thus, they encode the same protein. Here we report a novel variant, V9, and describe the mapping of all nine 5'UTR sequences within 40 kb upstream of exon 2. A cluster of three sequences, V2-V9-V3 (termed module A), lies furthest 5', and approx. 16 kb downstream is a second cluster of four exons, V7-V1-V4-V8 (module B). V6 is midway between modules A and B. Module B is about 18 kb upstream of V5, which lies adjacent to exon 2. HGHR expression is under developmental- and tissue-specific regulation, and expression of the variant mRNAs is related to their position within the 5'-flanking region; whereas module A (V2,V9,V3) and V5 variants are widely expressed, module B (V7,V1,V4,V8) and V6 variant mRNAs are detectable only in postnatal liver. Transcriptional start sites for V1 and V9 (representing the two different modules) were identified, showing that postnatal liver-specific expression of V1 is driven from two TAT boxes, whereas the ubiquitous V9 transcript has a single start site and a TATA-less promoter. V9 promoter activity was shown by in vivo and in vitro transfection assays, and an NF-Y binding site was demonstrated by electromobility shift assay. Thus, the regulatory regions of the hGHR gene are complex, and the clustering of